p28 peptide peptides - collagen-peptides-heart-health peptides The Potential of p28 Peptide: A Targeted Approach to Cancer Therapy

collagen-peptides-hair-growth-clinical-trial The p28 peptide, a meticulously designed fragment derived from the bacterial protein azurin, is emerging as a promising therapeutic agent in the fight against cancer.p28is an amphipathic, α-helical, cell penetratingpeptidecomposed of amino acids Leu50-Asp77 of azurin, a redox protein secreted from the opportunistic ... This anionic cell-penetrating peptide (CPP), composed of the amino acids Leu50-Asp77 of azurin, possesses a unique amphipathic and $\alpha$-helical structure that allows it to preferentially enter a wide variety of solid tumor cellsA novel peptide explicitly induces prostate cancer cell death by .... Its therapeutic potential lies in its ability to target and modulate the function of the critical tumor suppressor protein, p53, a peptide known for its role in preventing cancer formation.Azurin and its protein subunit P28 as an ...

Delving into the Mechanism of Action: Targeting p53

The efficacy of the p28 peptide is intrinsically linked to its interaction with p53. Research indicates that p28 binds to the DNA binding domain (DBD) of p53, leading to a post-translational increase in intracellular levels of wild-type p53Azurinp28 peptidebinds wild-type and mutant p53 protein and inhibits E3 ligase COP1-mediated ubiquitination of p53 by >80%, resulting in decreased proteasomal .... This stabilization of p53 is crucial because cancer cells often harbor mutations or alterations that lead to p53 degradation or loss of function. By binding to p53, p28 peptide inhibits its ubiquitylation mediated by E3 ligase COP1, thereby preventing p53 from undergoing proteasomal degradation作者：T Yamada·2013·被引用次数：73—p28, a cell penetratingpeptide, binds to the DNA binding domain (DBD) of p53, inducing a post-translational increase in intracellular levels of wild type .... This intricate mechanism effectively restores the protective functions of p53, which include inducing cell cycle arrest and initiating apoptotic cell death in cancer cells.

Furthermore, p28 has demonstrated the ability to disrupt the interaction between p53 and HDM2 (human double minute 2 homolog), another key regulator of p53 stability. By preventing HDM2 from binding to p53, p28 peptide further reinforces p53 levels and activity. This bypasses the conventional HDM2-mediated pathway, positioning p28 as a "first-in-class, non-HDM2-mediated peptide inhibitor" of p53 ubiquitination. This unique mode of action offers a novel therapeutic strategy, particularly for cancers where the p53-HDM2 axis is a critical oncogenic driverMayo Clinic discovers new role for protein to fight tumors.

p28 Peptide: Properties and Development

The p28 peptide is a water-soluble, amphipathic molecule with a molecular weight of approximately 2.9 kD.作者：RR Lulla·2016·被引用次数：156—Phase I trial ofp28(NSC745104), a non-HDM2-mediatedpeptideinhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central ... Its cell penetrating peptide (CPP) nature is a significant advantage, enabling it to efficiently cross cell membranes and reach its intracellular target within cancer cells. Studies have shown that upon administration, intracellular concentrations of p28 can reach significant levels, such as 120 ng/ml.

Various research entities and pharmaceutical companies are actively investigating the therapeutic potential of p28. For instance, CDG Therapeutics has been developing p28 for the intravenous treatment of p53-positive cancers. Clinical trials, including Phase I trials, have been conducted to evaluate the safety and efficacy of p28 in patients with advanced or recurrent cancersAzurin. These trials aim to assess p28's ability to induce apoptosis or cell cycle arrest and inhibit p53-positive tumor growths.

Beyond p53: Broader Anticancer Activity

While its primary mechanism involves p53 modulation, the p28 peptide exhibits broader anticancer activities.作者：A Joy·2026—This study investigates the potential anticancer activity of the azurin-derivedpeptide p28through its molecular interactions with human double ... It has been shown to preferentially enter a wide variety of solid tumor cells and induce cell cycle arrest and apoptotic cell death independent of its direct interaction with p53 in some contexts. This suggests that the peptide may possess multifaceted mechanisms for exerting its anti-proliferative effectsp28 peptide. Researchers are exploring the use of p28 in combination therapies, such as with current chemotherapeutic agents, to improve treatment efficacy, particularly for aggressive malignancies like GBM (glioblastoma multiforme).

The scientific community's interest in azurin and its derived peptides like p28 is growing due to their observed cytotoxicity and tumor-targeting capabilities. The structural characterization of the p28 peptide, including its $\alpha$-helical formation in solution, provides valuable insights into its molecular behavior and interaction with biological targets. Further research endeavors are focused on optimizing the expression and purification of bioactive p28 through different host systems, such as *Escherichia coli*, to facilitate its scalable production for therapeutic use.PNC-28 Peptide Explained: Targeting Cancer Cell ...

In conclusion, the p28 peptide represents a significant advancement in peptide-based cancer therapeutics. Its unique ability to penetrate cancer cells and specifically target the p53 pathway, along with its potential for broader cytotoxic effects, positions it as a promising candidate for developing novel and effective cancer treatments.A first-in-class, first-in-human, phase I trial of p28 ... Ongoing research and clinical trials are crucial to fully elucidate its therapeutic capabilities and bring this innovative peptide from the laboratory to patients in need.